Title: Gene Transfer by Pyro-Drive Jet Injector is a Novel Therapeutic Approach for Muscle Diseases.

[1]  H. Miyazaki,et al.  Potent intradermal gene expression of naked plasmid DNA in pig skin following pyro-drive jet injection. , 2020, Journal of pharmaceutical sciences.

[2]  T. Harada,et al.  Transcription factor old astrocyte specifically induced substance is a novel regulator of kidney fibrosis , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  T. Yamasoba,et al.  Single, high‐dose local injection of bFGF improves thyroarytenoid muscle atrophy after paralysis , 2020, The Laryngoscope.

[4]  Y. Kaneda,et al.  Stable Immune Response Induced by Intradermal DNA Vaccination by a Novel Needleless Pyro-Drive Jet Injector , 2019, AAPS PharmSciTech.

[5]  H. Miyazaki,et al.  Development of Pyro-Drive Jet Injector With Controllable Jet Pressure. , 2019, Journal of pharmaceutical sciences.

[6]  T. Weber,et al.  Human Cardiac Gene Therapy , 2018, Circulation research.

[7]  E. Vicaut,et al.  Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT‐HF randomized phase 2 trial , 2017, European journal of heart failure.

[8]  Alan D. Lopez,et al.  Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015 , 2017, Journal of the American College of Cardiology.

[9]  M. Katz,et al.  A Needleless Liquid Jet Injection Delivery Approach for Cardiac Gene Therapy. , 2017, Methods in molecular biology.

[10]  Amit N. Patel,et al.  Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial. , 2016, JAMA cardiology.

[11]  Akshay S. Desai,et al.  Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial , 2016, The Lancet.

[12]  K. Margulies,et al.  A Needleless Liquid Jet Injection Delivery Method for Cardiac Gene Therapy: a Comparative Evaluation Versus Standard Routes of Delivery Reveals Enhanced Therapeutic Retention and Cardiac Specific Gene Expression , 2014, Journal of Cardiovascular Translational Research.

[13]  Igor Rudan,et al.  Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis , 2013, The Lancet.

[14]  V. Roger.  Epidemiology of Heart Failure , 2013, Circulation research.

[15]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[16]  John P. Cooke,et al.  Murine Model of Hindlimb Ischemia , 2009, Journal of visualized experiments : JoVE.

[17]  F. Acín,et al.  Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease , 2009, Heart and Vessels.

[18]  E. Mohler,et al.  Management of peripheral arterial disease patients: comparing the ACC/AHA and TASC-II guidelines , 2008, Current medical research and opinion.

[19]  K. Webster,et al.  The effect of the controlled release of basic fibroblast growth factor from ionic gelatin-based hydrogels on angiogenesis in a murine critical limb ischemic model. , 2007, Biomaterials.

[20]  T. Ogihara,et al.  Needleless in vivo gene transfer into muscles by jet injection in combination with electroporation , 2004, The journal of gene medicine.

[21]  M. Aoki,et al.  Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease , 2004, Hypertension.

[22]  E. Konishi,et al.  Evidence for antigen production in muscles by dengue and Japanese encephalitis DNA vaccines and a relation to their immunogenicity in mice. , 2003, Vaccine.

[23]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[24]  J. Fallon,et al.  Fibroblast growth factors as multifunctional signaling factors. , 1999, International review of cytology.

[25]  S. Epstein,et al.  Basic fibroblast growth factor enhances myocardial collateral flow in a canine model. , 1994, The American journal of physiology.